[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 63, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 59, "title": "Executive VP, CFO & COO", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 658230, "exercisedValue": 0, "unexercisedValue": 73311}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 64, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 677467, "exercisedValue": 0, "unexercisedValue": 52440}, {"maxAge": 1, "name": "Ms. Laura  Kavanaugh", "title": "VP & Head of Legal", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 58, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "Senior VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kieron  Wesson Ph.D.", "title": "Vice President & Head of Chemistry Manufacturing Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramon  Polo M.B.A., Ph.D., Pharm.D.", "title": "Senior VP & Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.49, "open": 6.7, "dayLow": 6.7, "dayHigh": 7.465, "regularMarketPreviousClose": 6.49, "regularMarketOpen": 6.7, "regularMarketDayLow": 6.7, "regularMarketDayHigh": 7.465, "payoutRatio": 0.0, "beta": 2.66, "forwardPE": -1.0299242, "volume": 77898, "regularMarketVolume": 77898, "averageVolume": 75396, "averageVolume10days": 76470, "averageDailyVolume10Day": 76470, "bid": 5.31, "ask": 8.6, "bidSize": 2, "askSize": 2, "marketCap": 45044220, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 29.54, "allTimeHigh": 937.75, "allTimeLow": 3.76, "priceToSalesTrailing12Months": 17.023514, "fiftyDayAverage": 9.4209, "twoHundredDayAverage": 8.438975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -47986780, "profitMargins": 0.0, "floatShares": 3138388, "sharesOutstanding": 5353582, "sharesShort": 268943, "sharesShortPriorMonth": 258242, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0437, "heldPercentInsiders": 0.10366, "heldPercentInstitutions": 0.53366, "shortRatio": 3.91, "shortPercentOfFloat": 0.0513, "impliedSharesOutstanding": 6153582, "bookValue": 11.674, "priceToBook": 0.6270345, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -86462000, "trailingEps": -13.54, "forwardEps": -7.10732, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -18.136, "enterpriseToEbitda": 0.559, "52WeekChange": -0.765704, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 7.32, "targetHighPrice": 175.0, "targetLowPrice": 20.0, "targetMeanPrice": 68.2, "targetMedianPrice": 50.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 99096000, "totalCashPerShare": 16.104, "ebitda": -85820000, "totalDebt": 6065000, "quickRatio": 4.507, "currentRatio": 4.704, "totalRevenue": 2646000, "debtToEquity": 8.443, "revenuePerShare": 0.299, "returnOnAssets": -0.54704, "returnOnEquity": -1.4182401, "grossProfits": -65800000, "freeCashflow": -45352752, "operatingCashflow": -79161000, "revenueGrowth": -0.416, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -38.27395, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 12.7889, "regularMarketPrice": 7.32, "corporateActions": [], "postMarketTime": 1770412204, "regularMarketTime": 1770411602, "exchange": "NCM", "fiftyTwoWeekChangePercent": -76.5704, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -13.54, "epsForward": -7.10732, "epsCurrentYear": -7.58788, "priceEpsCurrentYear": -0.96469635, "fiftyDayAverageChange": -2.1009002, "fiftyDayAverageChangePercent": -0.22300418, "twoHundredDayAverageChange": -1.1189752, "twoHundredDayAverageChangePercent": -0.13259609, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "cryptoTradeable": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "postMarketChangePercent": 0.0, "postMarketPrice": 7.32, "postMarketChange": 0.0, "regularMarketChange": 0.83, "regularMarketDayRange": "6.7 - 7.465", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 75396, "fiftyTwoWeekLowChange": 3.5600002, "fiftyTwoWeekLowChangePercent": 0.9468086, "fiftyTwoWeekRange": "3.76 - 29.54", "fiftyTwoWeekHighChange": -22.220001, "fiftyTwoWeekHighChangePercent": -0.7522004, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]